BOSTON – Abcore®, part of the Antibody Solutions (AbS) business division under Fortis Life Sciences®, has announced the launch of its AbNano™ Anti-T-Cell VHH Library, a naturally derived platform designed to accelerate therapeutic antibody discovery targeting T-cell surface proteins. The new library builds on the company’s existing AbNano™ Naïve VHH Library and marks a significant expansion in its immunology research capabilities.
The AbNano Anti-T-Cell Library is the first of its kind to be developed using a native T-cell-based immunization strategy, enabling researchers to rapidly identify antibodies that bind to complex and context-sensitive T-cell surface proteins. With an estimated one billion unique VHH molecules, the library offers a diverse population of target-binding candidates that are typically difficult and time-consuming to generate through traditional methods.
“Abcore’s novel AbNano Anti-T-Cell Library enables rapid early therapeutic discovery for research labs, biotech companies, and pharma,” said Sam Sugerman, Director of VHH Discovery at Fortis Life Sciences. “By combining error-prone PCR diversification with whole, unstimulated T-cells, Abcore has developed an effective library that reveals unique binding modalities applicable across bioprocessing, diagnostics, and early-stage therapeutic discovery.”
T-cells pose distinct challenges for antibody research due to the complexity of their surface proteins, which vary in expression depending on physiological and environmental conditions. The AbNano Anti-T-Cell Library directly addresses these challenges by using error-prone PCR diversification to probe a wide range of novel antibody sequences. This approach enables the discovery of atypical and diverse binding modes. The platform has already validated key binders for important targets such as CD3ε and CD8αβ.
The library is positioned to support a broad range of applications, from bioprocess optimization to preclinical therapeutic research, and is now available to collaborators through Abcore’s early access program. To encourage adoption, the company is offering limited-time promotional packages to partners interested in evaluating the AbNano VHH Libraries through either solid-phase or solution-phase panning methods.
With this launch, Abcore continues to enhance its reputation as a leader in VHH discovery and antibody platform innovation, particularly within the rapidly growing field of single-domain antibodies for immunological research and therapeutic development.
